A Phase 3, Open-Label Study to Assess the Long-Term Safety of Dexlansoprazole MR (60 mg QD and 90 mg QD).

Trial Profile

A Phase 3, Open-Label Study to Assess the Long-Term Safety of Dexlansoprazole MR (60 mg QD and 90 mg QD).

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2016

At a glance

  • Drugs Dexlansoprazole (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Takeda Global Research and Development Center; TAP Pharmaceutical Products
  • Most Recent Events

    • 19 May 2010 Quality-of-life results presented at Digestive Disease Week 2010.
    • 18 Aug 2009 Primary endpoints identified as reported by ClinicalTrials.gov.
    • 04 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top